ArticleCancer research communications2026
Two Molecular Subgroups Predict Most Recurrences in Advanced Laryngeal Squamous Cell Carcinoma.
Article in Cancer research communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
The aim of this study was to test whether intratumoral heterogeneity explains inconsistent reports on VEGF-A as a prognostic marker in laryngeal squamous cell carcinoma (LSCC) and to identify expression phenotypes (mRNA/miRNA) associated with recurrence. In a prospective cohort of 60 patients with T3/T4 LSCC undergoing primary laryngectomy, we sampled four regions per case (tumor surface, tumor depth, peritumoral mucosa ≤1 cm, and paired distant normal mucosa). mRNA levels of hypoxia-inducible factor (HIF) 1α/2α/3α, VEGF-A, VEGFR1/2, and ETS-1 were quantified by qRT-PCR; cohort-matched miRNA profiling (microarray with qRT-PCR validation) was integrated. Elevated VEGF-A at tumor depth predicted recurrence (log-rank P = 0.0001), whereas surface VEGF-A had no prognostic value (P = 0.170). Pairwise testing confirmed higher VEGF-A at depth versus surface (Wilcoxon P = 0.026). A subgroup with depth VEGF-A relative quantification (RQ) > 2 and HIF1α RQ < 2 showed a 64% recurrence rate. An independent subgroup defined by high miR-93-5p/miR-144-3p/miR-210-3p expression also had significantly worse outcomes. The two subgroups were non-overlapping in most patients and accounted for 76% of recurrences. The prognostic relevance of VEGF-A in LSCC is region dependent, with clinically meaningful value confined to tumor depth. Together with a high-risk three-miRNA signature, these findings delineate two molecular subgroups capturing most recurrences and may inform sampling strategies and risk stratification. SIGNIFICANCE: We demonstrate that VEGF-A has prognostic value in laryngeal carcinoma only when assessed at tumor depth. Alongside a distinct high-risk miRNA signature, we define two molecular subgroups accounting for most recurrences, highlighting the clinical importance of spatial heterogeneity in biomarker evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.